Implications of Cellular Immaturity in Necrosis and Microvascularization in Glioblastomas IDH-Wild-Type

Abstract

Necrosis and increased microvascular density in glioblastoma IDH-wild-type are the consequence of both hypoxia and cellular immaturity. Our study aimed to identify the main clinical-imaging and morphogenetic risk factors associated with tumor necrosis and microvascular in the prognosis of patient survival. We performed a retrospective study (10 years) in which we identified 39 cases. We used IDH1, Ki-67 and Nestin immunomarkers, as well as CDKN2A by FISH. The data were analyzed using SPSS Statistics. The clinical characterization identified only age over 50 years as a risk factor (HR = 3.127). The presence of the tumor residue, as well as the absence of any therapeutic element from the trimodal treatment, were predictive factors of mortality (HR = 1.024, respectively HR = 7.460). Cellular immaturity quantified by Nestin was associated with reduced overall survival (p = 0.007). Increased microvascular density was associated with an increased proliferative index (p = 0.009) as well as alterations of the CDKN2A gene (p < 0.001). CDKN2A deletions and cellular immaturity were associated with an increased percentage of necrosis (p < 0.001, respectively, p = 0.017). The main risk factors involved in the unfavorable prognosis are moderate and increased Nestin immunointensity, as well as the association of increased microvascular density with age over 50 years. Necrosis was not a risk factor.

Comparison of Ki67 Proliferation Index in Gastrointestinal Non-Hodgkin Large B-Cell Lymphomas: The Conventional Method of Evaluation or AI Evaluation?

“…However, the intra-and interobserver variability of Ki-67, which is dependent on the heterogeneity of the tumor and the area under examination, discourages it from being validated as a prognostic factor [41]. In our study, the agreement coefficient between the conventional method and the AI method indicates an excellent level of reliability (ICC1-0.970, ICC2-0.990).…”

Glioblastoma-Derived Small Extracellular Vesicles: Nanoparticles for Glioma Treatment

“…Several active efforts to re-evaluate existing or investigate new anti-GBM agents are ongoing, and our results expand the possibilities of investigating other combinatorial therapies. Another important aspect of GBM treatment includes the fact that chemotherapeutic regimens are largely non-selective and cytotoxic in nature, and despite all the efforts, almost all patients experience tumor progression, with nearly universal mortality and a median survival of less than 15 months, depending on several risk factors [ 60 ]. There is a need to optimize the balance between effectiveness and toxicity, and the use of small EVs may help to reduce the amount of drug given to a patient in order to reach the same effect.…”